Updated: 26th June 2026
Reviewed by: David Small BSc (Hons), MSc, MTOPRA (Founder & CEO)
What Is Medical Device Clinical Evaluation?
Clinical Evaluation is the systematic and continuous process of collecting, appraising and analysing clinical data to demonstrate that a medical device is safe, achieves its intended clinical performance and delivers an acceptable benefit-risk profile when used as intended. Under the European Medical Device Regulation (EU MDR) 2017/745, clinical evaluation is not a one-off activity performed solely to obtain CE marking; it is an ongoing process that continues throughout the entire lifecycle of a medical device.
Every manufacturer placing a medical device on the European market must generate sufficient clinical evidence to support conformity with the General Safety and Performance Requirements (GSPRs). The depth of clinical evaluation depends on factors such as the device’s classification, intended purpose, novelty, clinical claims and the level of clinical risk associated with its use. While lower-risk devices may rely heavily on published scientific literature and post-market clinical experience, higher-risk or novel technologies often require clinical investigations to generate additional evidence.
Clinical evaluation forms one of the core pillars of the EU MDR alongside risk management, technical documentation, quality management and post-market surveillance. Together, these activities provide regulators, Notified Bodies, healthcare professionals and patients with confidence that a device performs as intended and that its benefits continue to outweigh any identified risks throughout its commercial life.
This guide explains every stage of the clinical evaluation process, from planning and identifying relevant clinical evidence through to preparing a Clinical Evaluation Report (CER), maintaining compliance through Post-Market Clinical Follow-up (PMCF) and updating clinical evidence using Post-Market Surveillance (PMS). Whether you are developing a new device or maintaining an existing CE-marked product, understanding clinical evaluation is essential for achieving and maintaining regulatory compliance under the EU MDR.
New to the EU MDR?
If you're looking for a complete introduction to Regulation (EU) 2017/745, including device classification, General Safety and Performance Requirements (GSPRs), Clinical Evaluation, Technical Documentation, Risk Management, Notified Body requirements and CE marking, explore our EU MDR for Beginners: A Comprehensive Guide.
Why Clinical Evaluation Is Essential Under the EU MDR
Clinical evaluation is far more than a regulatory document—it is the process that demonstrates a medical device can be used safely and effectively by patients while delivering meaningful clinical benefits. Rather than relying solely on laboratory testing or bench performance, manufacturers must evaluate real clinical evidence to show that the device performs as intended under normal conditions of use.
Under Article 61 and Annex XIV of the EU MDR, manufacturers must establish, document, implement and continuously update a clinical evaluation for every medical device, regardless of its classification. The evidence gathered supports numerous regulatory activities, including conformity assessment, benefit-risk analysis, labelling, intended purpose, risk management, Post-Market Surveillance (PMS) and, where appropriate, Post-Market Clinical Follow-up (PMCF).
A robust clinical evaluation also supports wider business objectives by helping manufacturers:
- Demonstrate conformity with the EU MDR.
- Support CE marking and ongoing market access.
- Substantiate clinical and marketing claims with objective evidence.
- Confirm that the benefits of the device outweigh any residual risks.
- Identify evidence gaps requiring additional clinical data.
- Support Risk Management in accordance with ISO 14971.
- Strengthen Technical Documentation for Notified Body review.
- Continuously monitor device performance throughout its lifecycle.
Ultimately, clinical evaluation provides the scientific and clinical foundation upon which the safety, performance and regulatory compliance of every medical device is built.
How Clinical Evaluation Fits into EU MDR Compliance
Clinical Evaluation does not exist in isolation. Instead, it forms one of the central components of the technical documentation required under the EU Medical Device Regulation (EU MDR) 2017/745. Every conclusion reached during a Clinical Evaluation influences other areas of regulatory compliance, while information generated elsewhere within the Quality Management System feeds back into the ongoing clinical evaluation process.
For example, the device’s intended purpose defines the clinical questions that must be answered during the evaluation. Risk Management identifies hazards and residual risks that require clinical evidence to demonstrate acceptability. Biological Evaluation supports the safety assessment of materials in contact with the body, while usability engineering helps demonstrate that the device can be used safely by its intended users. Once the device is placed on the market, Post-Market Surveillance (PMS) and Post-Market Clinical Follow-up (PMCF) generate new clinical data that must be reviewed and incorporated into future updates of the Clinical Evaluation Report (CER).
This continuous exchange of information ensures that manufacturers maintain an accurate understanding of their device’s safety, clinical performance and benefit-risk profile throughout its lifecycle. Rather than producing separate documents that are reviewed independently, the EU MDR expects manufacturers to maintain an integrated technical documentation system where clinical evaluation supports, and is supported by, every major compliance activity.
Clinical Evaluation's Relationship with Other MDR Requirements
| Regulatory Activity | Relationship to Clinical Evaluation |
|---|---|
| Intended Purpose | Defines the clinical claims and intended clinical benefits that must be supported by evidence. |
| General Safety and Performance Requirements (GSPRs) | Clinical evidence demonstrates conformity with relevant safety and performance requirements. |
| Risk Management (ISO 14971) | Clinical data confirms whether identified risks remain acceptable when balanced against the device’s clinical benefits. |
| Biological Evaluation (ISO 10993) | Provides supporting evidence that materials are biologically safe for their intended use. |
| Clinical Investigation | Generates original clinical evidence where existing literature or equivalent device data is insufficient. |
| Technical Documentation | The Clinical Evaluation Report forms a key component of the MDR Technical File submitted during conformity assessment. |
| Post-Market Surveillance (PMS) | Collects real-world clinical experience used to verify continued safety and performance. |
| Post-Market Clinical Follow-up (PMCF) | Generates additional clinical evidence after market release to address uncertainties or confirm long-term performance. |
| Clinical Evaluation Report (CER) | Documents the methods, evidence, appraisal, analysis and conclusions of the clinical evaluation process. |
Why This Integration Matters
Manufacturers sometimes view clinical evaluation as a standalone document prepared shortly before CE marking. In reality, it is a continuous process that draws information from every stage of the medical device lifecycle. Changes to the intended purpose, design, manufacturing process, risk profile, clinical evidence or post-market performance may all require the Clinical Evaluation Report to be reviewed and updated.
This integrated approach helps ensure that regulatory decisions are based on current clinical evidence rather than historical assumptions, enabling manufacturers to maintain compliance with the EU MDR while continually demonstrating that their devices remain safe, perform as intended and continue to deliver a favourable benefit-risk profile throughout their commercial life.
The Medical Device Clinical Evaluation Process
Clinical evaluation follows a structured, evidence-based methodology designed to determine whether a medical device is safe, achieves its intended clinical performance and maintains an acceptable benefit-risk profile throughout its lifecycle. Rather than being a single report produced before CE marking, clinical evaluation is an ongoing process that begins during device development and continues through commercialisation and post-market monitoring.
Under Annex XIV of the EU MDR, manufacturers are expected to systematically plan, collect, appraise and analyse relevant clinical data before documenting their conclusions within a Clinical Evaluation Report (CER). As new information becomes available through Post-Market Surveillance (PMS), Post-Market Clinical Follow-up (PMCF), scientific publications or clinical investigations, the evaluation must be reviewed and updated to ensure it continues to reflect the current state of knowledge.
While the amount of clinical evidence required depends on factors such as device classification, intended purpose and clinical risk, every manufacturer should follow the same structured methodology to ensure their clinical evaluation is robust, objective and fully traceable.
The Seven Stages of Clinical Evaluation
1. Develop a Clinical Evaluation Plan (CEP)
The process begins with a Clinical Evaluation Plan, which defines the objectives, scope and methodology of the evaluation. The CEP identifies the intended purpose of the device, target patient population, applicable regulatory requirements, clinical questions to be answered, data sources, appraisal methods and update strategy.
This plan provides the framework for conducting a consistent, transparent and reproducible clinical evaluation.
2. Identify Relevant Clinical Evidence
Manufacturers must identify all available clinical data relevant to the device. Evidence may originate from:
- Published scientific literature
- Clinical investigations
- Equivalent devices (where permitted)
- Post-Market Surveillance (PMS)
- Post-Market Clinical Follow-up (PMCF)
- Device registries and real-world evidence
- Complaint and vigilance data
The objective is to gather sufficient high-quality evidence to demonstrate conformity with the applicable General Safety and Performance Requirements (GSPRs).
3. Critically Appraise the Evidence
Not all clinical evidence carries equal weight. Each study, publication or dataset should be critically assessed for its scientific quality, relevance, validity and potential bias. Manufacturers must determine whether the available evidence is sufficiently robust to support conclusions regarding safety and clinical performance.
Weak, outdated or poorly designed evidence should not be relied upon without appropriate justification.
4. Analyse the Clinical Data
Following appraisal, the evidence is analysed collectively to determine whether the device achieves its intended purpose and whether the demonstrated clinical benefits outweigh any identified residual risks. The analysis should also identify any uncertainties, limitations or evidence gaps that may require further investigation.
Where appropriate, this analysis should be considered alongside the device’s Risk Management File and Biological Evaluation to ensure consistency across the technical documentation.
5. Identify Evidence Gaps
If the available evidence is insufficient to fully demonstrate safety or clinical performance, manufacturers must determine how these gaps will be addressed. This may involve conducting additional literature reviews, generating Post-Market Clinical Follow-up (PMCF) data or performing a clinical investigation where necessary.
Identifying evidence gaps early helps avoid delays during Notified Body review and supports a proactive regulatory strategy.
6. Prepare the Clinical Evaluation Report (CER)
The findings of the clinical evaluation are documented within the Clinical Evaluation Report. The CER records the evaluation methodology, evidence sources, critical appraisal, clinical analysis and final conclusions regarding safety, clinical performance and benefit-risk.
The report forms a key component of the MDR Technical Documentation submitted during conformity assessment.
7. Maintain the Clinical Evaluation Throughout the Device Lifecycle
Clinical evaluation does not end once a device has obtained CE marking. Manufacturers must continuously monitor new clinical information generated through PMS, PMCF, complaint handling, vigilance activities and scientific literature to ensure the Clinical Evaluation Report remains current.
Whenever significant new evidence becomes available, or when changes are made to the device, intended purpose or risk profile, the clinical evaluation should be reviewed and updated accordingly.
Clinical Evaluation Is a Continuous Process
One of the most significant changes introduced by the EU MDR is the expectation that clinical evaluation becomes a living process rather than a one-time regulatory exercise. Manufacturers are expected to continually reassess their clinical evidence as new information emerges, ensuring that the conclusions documented within the Clinical Evaluation Report remain accurate throughout the product’s lifecycle.
This continuous approach strengthens patient safety, supports ongoing regulatory compliance and enables manufacturers to demonstrate that their devices continue to deliver safe, effective and clinically meaningful outcomes long after they have been placed on the market.
What Counts as Clinical Evidence?
Clinical evaluation is only as strong as the evidence on which it is based. Under the EU MDR, manufacturers must identify, collect, appraise and analyse all relevant clinical data to demonstrate that their medical device achieves its intended purpose, performs safely and maintains an acceptable benefit-risk profile throughout its lifecycle.
The MDR does not prescribe a single source of clinical evidence. Instead, manufacturers are expected to consider all relevant information, using evidence that is appropriate for the device’s intended purpose, level of innovation, clinical risk and maturity. Higher-risk or novel devices generally require more extensive clinical evidence than well-established technologies with a long history of safe clinical use.
Importantly, clinical evidence should never be selected simply because it supports a favourable conclusion. Manufacturers must perform an objective and balanced evaluation that considers both positive and negative findings, ensuring that the Clinical Evaluation Report reflects the totality of available evidence.
Common Sources of Clinical Evidence
Manufacturers may use one or more of the following evidence sources during clinical evaluation.
| Clinical Evidence Source | Purpose |
|---|---|
| Scientific Literature | Published clinical studies, systematic reviews and peer-reviewed journals demonstrating safety and clinical performance. |
| Clinical Investigations | Prospective clinical studies conducted specifically to generate clinical evidence for the device. |
| Equivalent Devices | Clinical data from an equivalent device where equivalence can be fully justified in accordance with the EU MDR. |
| Post-Market Surveillance (PMS) | Real-world data collected after the device has been placed on the market, including complaints, trend reports and customer feedback. |
| Post-Market Clinical Follow-up (PMCF) | Ongoing collection of clinical data to confirm long-term safety, clinical performance and continued benefit-risk. |
| Registries and Real-World Evidence | Information obtained from patient registries, healthcare databases and routine clinical practice. |
| Vigilance Data | Serious incidents, Field Safety Corrective Actions (FSCAs) and trend analysis that help evaluate emerging risks. |
| Published Standards and Clinical Guidelines | Recognised standards and professional guidance that support the current state of the art. |
Evaluating the Quality of Clinical Evidence
Not all clinical evidence has the same scientific value. Each dataset should be critically appraised to determine its relevance, reliability and suitability for supporting regulatory conclusions.
When reviewing clinical evidence, manufacturers should consider factors such as:
- Relevance to the device’s intended purpose.
- Similarity of the patient population.
- Clinical significance of the measured outcomes.
- Study design and methodology.
- Sample size and duration of follow-up.
- Statistical validity of the results.
- Potential sources of bias.
- Whether the evidence reflects the current state of the art.
Evidence that is outdated, poorly designed or not directly applicable to the device should be carefully justified or excluded from the evaluation.
Building the Totality of Clinical Evidence
Rather than relying on a single clinical study, manufacturers are expected to assess the totality of available evidence. A robust clinical evaluation typically combines multiple sources of information, allowing conclusions to be supported by a broad body of clinical data.
For example, a Clinical Evaluation Report may include published scientific literature, data from clinical investigations, post-market surveillance findings, PMCF activities and real-world clinical experience. When considered together, these complementary evidence sources provide a more comprehensive assessment of device safety, clinical performance and benefit-risk than any individual dataset alone.
This evidence-based approach enables manufacturers to demonstrate that regulatory decisions are supported by objective clinical data while ensuring the Clinical Evaluation remains current as new evidence becomes available throughout the medical device lifecycle.
The Clinical Evaluation Plan (CEP)
Every robust clinical evaluation begins with a Clinical Evaluation Plan (CEP). Required under Annex XIV of the EU MDR, the CEP establishes the objectives, scope and methodology that will be followed throughout the clinical evaluation process. Rather than collecting evidence without a defined strategy, manufacturers are expected to plan how relevant clinical data will be identified, appraised, analysed and maintained before the evaluation begins.
The Clinical Evaluation Plan acts as the roadmap for the entire evaluation. It ensures that the process is systematic, transparent and reproducible while demonstrating to Notified Bodies that clinical evidence has been assessed using a scientifically justified methodology. Although the CEP is a separate document from the Clinical Evaluation Report (CER), it forms the foundation upon which the final report is built.
Developing a comprehensive Clinical Evaluation Plan at an early stage also helps manufacturers identify potential evidence gaps before they become regulatory issues. This allows sufficient time to undertake additional literature reviews, generate Post-Market Clinical Follow-up (PMCF) data or conduct clinical investigations where necessary.
What Should a Clinical Evaluation Plan Include?
While the exact format may vary depending on the complexity of the device, a Clinical Evaluation Plan will typically include the following elements.
| Clinical Evaluation Plan Element | Purpose |
|---|---|
| Device Description | Defines the device, intended purpose, indications, target patient population and clinical claims. |
| Regulatory Scope | Identifies the applicable requirements of the EU MDR and Annex XIV. |
| Clinical Questions | Specifies the safety and performance questions the evaluation must answer. |
| Evidence Sources | Defines which clinical data sources will be searched and evaluated, including literature, clinical investigations, PMS and PMCF. |
| Literature Search Strategy | Describes the databases, keywords, inclusion and exclusion criteria, and search methodology. |
| Critical Appraisal Methodology | Explains how the quality, relevance and scientific validity of clinical evidence will be assessed. |
| Clinical Data Analysis | Defines how evidence will be synthesised to assess safety, clinical performance and benefit-risk. |
| Update Strategy | Establishes when and how the clinical evaluation will be reviewed and updated throughout the device lifecycle. |
Why the CEP Is Important
A well-developed Clinical Evaluation Plan provides consistency throughout the evaluation and reduces the likelihood of regulatory deficiencies during Notified Body review. Without a clearly documented methodology, manufacturers may struggle to justify why certain evidence was included, excluded or given greater weight during the evaluation.
The CEP also supports traceability by demonstrating that every conclusion within the Clinical Evaluation Report is based on a predefined, objective process rather than retrospective judgement. This transparency is particularly important for higher-risk devices, where clinical evidence is subject to greater regulatory scrutiny.
Ultimately, the Clinical Evaluation Plan helps ensure that clinical evaluation remains a structured scientific exercise rather than simply a document produced to satisfy regulatory requirements. By establishing a robust methodology from the outset, manufacturers can produce stronger Clinical Evaluation Reports and maintain clinical evidence more effectively throughout the device lifecycle.
The Clinical Evaluation Report (CER)
The Clinical Evaluation Report (CER) is the documented outcome of the clinical evaluation process. It brings together all relevant clinical evidence, critically appraises the available data and presents the manufacturer’s conclusions regarding the safety, clinical performance and benefit-risk profile of the medical device.
Unlike the Clinical Evaluation Plan (CEP), which defines how the evaluation will be conducted, the CER documents what was actually undertaken, the evidence that was reviewed and the conclusions that were reached. It forms a key part of the technical documentation submitted during conformity assessment and is one of the documents most closely scrutinised by Notified Bodies during MDR certification.
A well-prepared CER should demonstrate that sufficient clinical evidence exists to support the device’s intended purpose, substantiate any clinical claims and confirm ongoing conformity with the applicable General Safety and Performance Requirements (GSPRs). Importantly, the report should present a balanced assessment of all relevant evidence, including any limitations, uncertainties or conflicting findings.
What Should a Clinical Evaluation Report Include?
Although the structure of a CER may vary depending on the complexity of the device, it will typically contain the following sections.
| Clinical Evaluation Report Section | Purpose |
|---|---|
| Executive Summary | Provides an overview of the evaluation, key findings and final conclusions. |
| Device Description | Describes the device, intended purpose, indications, contraindications and target patient population. |
| Regulatory Background | Identifies the applicable MDR requirements and standards. |
| Clinical Evaluation Methodology | Summarises the methodology defined within the Clinical Evaluation Plan. |
| Clinical Evidence Review | Presents the clinical data identified from literature, clinical investigations, PMS, PMCF and other evidence sources. |
| Critical Appraisal | Evaluates the quality, relevance and scientific validity of the available evidence. |
| Clinical Data Analysis | Assesses whether the evidence demonstrates safety, clinical performance and an acceptable benefit-risk profile. |
| Conclusions | States whether sufficient clinical evidence exists to support continued compliance with the EU MDR. |
| References and Appendices | Includes supporting literature, search strategies and other relevant documentation. |
Keeping the CER Up to Date
The Clinical Evaluation Report is not a document that is written once and then archived. Under the EU MDR, manufacturers are expected to review and update the CER whenever new clinical information becomes available or when significant changes are made to the device.
Examples that may trigger a CER update include:
- New Post-Market Surveillance (PMS) findings.
- Results from Post-Market Clinical Follow-up (PMCF) activities.
- Newly published scientific literature.
- Clinical investigation results.
- Changes to the device design or intended purpose.
- New or emerging risks identified through Risk Management.
- Field Safety Corrective Actions (FSCAs) or vigilance reports.
Maintaining an up-to-date CER demonstrates that manufacturers are continually monitoring the clinical performance of their devices and that regulatory decisions remain supported by current evidence rather than historical data.
A CER Is More Than a Regulatory Requirement
Many manufacturers view the Clinical Evaluation Report simply as a document required for CE marking. In reality, it is the primary record demonstrating that a medical device continues to deliver safe and effective clinical outcomes throughout its lifecycle.
A comprehensive CER supports regulatory compliance, strengthens Technical Documentation, facilitates Notified Body review and provides confidence that the device continues to achieve its intended purpose while maintaining an acceptable benefit-risk profile. When integrated with Risk Management, Post-Market Surveillance and PMCF activities, the CER becomes a living document that evolves alongside the device itself.
Need to Prepare a Clinical Evaluation Report (CER)?
This guide introduces the role of the Clinical Evaluation Report within the EU MDR. If you need detailed guidance on CER structure, regulatory requirements, clinical evidence, benefit-risk assessment, literature reviews and Notified Body expectations, read our Clinical Evaluation Report: EU MDR Requirements.
Post-Market Clinical Follow-up (PMCF)
For many medical devices, clinical evaluation does not end when CE marking is achieved. The EU MDR requires manufacturers to continually collect and assess clinical data throughout the device’s commercial life to confirm that it continues to perform safely and effectively under real-world conditions. This ongoing process is known as Post-Market Clinical Follow-up (PMCF).
PMCF forms part of the manufacturer’s wider Post-Market Surveillance (PMS) system and is specifically focused on generating additional clinical evidence after a device has been placed on the market. The objective is to confirm the continued safety, clinical performance and benefit-risk profile of the device while identifying previously unknown risks, adverse events or long-term performance issues that may not have been apparent during pre-market evaluation.
Not every medical device requires extensive PMCF activities. The scope should be proportionate to factors such as the device classification, intended purpose, novelty, clinical risk and the maturity of the available clinical evidence. However, manufacturers must always justify their PMCF strategy within their technical documentation.
Typical PMCF Activities
Manufacturers may obtain post-market clinical evidence through a variety of activities, depending on the nature of the device and the objectives of the PMCF programme.
| PMCF Activity | Purpose |
|---|---|
| PMCF Clinical Studies | Collect prospective clinical data under normal conditions of use. |
| User and Patient Surveys | Obtain feedback on device performance, usability and clinical outcomes. |
| Device Registries | Analyse long-term performance data from patient registries or national databases. |
| Scientific Literature Reviews | Monitor newly published evidence relevant to the device or similar technologies. |
| Complaint and Vigilance Analysis | Identify emerging safety trends and opportunities for improvement. |
| Real-World Clinical Data | Evaluate routine clinical use to confirm ongoing safety and effectiveness. |
Why PMCF Is Important
The clinical environment continually evolves. New treatment options, updated clinical guidelines, emerging scientific evidence and long-term device performance can all influence the benefit-risk profile of a medical device. PMCF enables manufacturers to proactively monitor these changes rather than relying solely on evidence collected before CE marking.
PMCF activities help manufacturers to:
- Confirm continued clinical performance in routine clinical practice.
- Verify that the benefit-risk profile remains favourable.
- Identify rare or long-term adverse events.
- Detect emerging clinical trends and safety signals.
- Support updates to the Clinical Evaluation Report (CER).
- Strengthen Risk Management activities.
- Demonstrate ongoing compliance with the EU MDR.
For higher-risk devices, PMCF often represents one of the most important sources of new clinical evidence throughout the product lifecycle.
PMCF Supports Continuous Clinical Evaluation
Clinical evaluation under the EU MDR is intended to be a living process. Information generated through PMCF should be reviewed alongside Post-Market Surveillance data, Risk Management activities, scientific literature and vigilance reporting to determine whether the conclusions within the Clinical Evaluation Report remain valid.
Where new evidence identifies changes in clinical performance, emerging risks or opportunities for improvement, manufacturers should update the Clinical Evaluation Report, Risk Management File and Technical Documentation accordingly. By integrating PMCF into the wider quality and regulatory system, manufacturers can ensure that clinical evaluation continues to reflect the current clinical experience of the device throughout its lifecycle.
Need to Develop a Post-Market Clinical Follow-up (PMCF) Programme?
Post-Market Clinical Follow-up (PMCF) is a key component of Clinical Evaluation under the EU MDR, helping manufacturers collect ongoing clinical evidence after CE marking. Learn how to develop compliant PMCF Plans, PMCF Evaluation Reports (PMCFERs), select appropriate data collection methods and integrate PMCF with your Clinical Evaluation Report (CER), Risk Management and Post-Market Surveillance activities in our Guide to Post-Market Clinical Follow-up (PMCF).
Clinical Evaluation Throughout the Medical Device Lifecycle
One of the most significant changes introduced by the EU MDR is the expectation that clinical evaluation becomes a continuous lifecycle activity rather than a one-time exercise performed before CE marking. Manufacturers are expected to continually review new clinical evidence, reassess the benefit-risk profile of their devices and update their technical documentation whenever significant new information becomes available.
Clinical evaluation therefore sits at the centre of the manufacturer’s regulatory system. It draws information from multiple processes, including Risk Management, Biological Evaluation, Clinical Investigations, Post-Market Surveillance (PMS), Post-Market Clinical Follow-up (PMCF) and vigilance activities. At the same time, the conclusions reached during the Clinical Evaluation influence labelling, intended purpose, clinical claims and ongoing regulatory decision-making.
This integrated approach ensures that manufacturers maintain an accurate understanding of how their devices perform throughout their commercial life while continually demonstrating conformity with the EU MDR.
How Clinical Evaluation Connects to Other Regulatory Activities
| Regulatory Activity | How It Supports Clinical Evaluation |
|---|---|
| Risk Management (ISO 14971) | Clinical evidence confirms whether identified risks remain acceptable when balanced against the device’s clinical benefits. |
| Biological Evaluation (ISO 10993) | Demonstrates the biological safety of materials and supports the overall safety assessment. |
| Usability Engineering (IEC 62366-1) | Provides evidence that intended users can operate the device safely and effectively. |
| Clinical Investigations | Generate original clinical data where existing evidence is insufficient. |
| Technical Documentation | The Clinical Evaluation Report forms a key component of the MDR Technical File. |
| Post-Market Surveillance (PMS) | Supplies real-world performance data used to verify continued safety and effectiveness. |
| Post-Market Clinical Follow-up (PMCF) | Generates ongoing clinical evidence throughout the product lifecycle. |
| Vigilance | Identifies serious incidents and emerging safety signals requiring clinical reassessment. |
| General Safety and Performance Requirements (GSPRs) | Clinical evidence helps demonstrate conformity with the applicable safety and performance requirements. |
Maintaining Clinical Evaluation After CE Marking
Achieving CE marking is not the end of the clinical evaluation process. Manufacturers should continually monitor both internal and external sources of clinical information, including scientific literature, customer feedback, complaints, vigilance reports, PMCF activities and changes in the state of the art.
Whenever significant new information becomes available, manufacturers should determine whether it affects the device’s clinical performance, safety or benefit-risk profile. Where necessary, the Clinical Evaluation Report, Risk Management File and Technical Documentation should be updated to reflect the latest evidence.
This continuous review process helps ensure that regulatory decisions remain evidence-based while supporting patient safety and ongoing compliance with the EU MDR throughout the entire medical device lifecycle.
Clinical Evaluation vs Clinical Investigation
Although the terms are often used interchangeably, Clinical Evaluation and Clinical Investigation are not the same. A Clinical Evaluation is the ongoing process of assessing all available clinical evidence to demonstrate that a medical device is safe, performs as intended and maintains an acceptable benefit-risk profile. A Clinical Investigation, on the other hand, is one potential source of clinical evidence and involves conducting a structured clinical study to generate new data.
Many medical devices can be successfully evaluated using existing scientific literature, post-market experience and other relevant clinical evidence without undertaking a new Clinical Investigation. However, for novel technologies, higher-risk devices or products where existing evidence is insufficient, manufacturers may need to perform a Clinical Investigation to generate the data required to demonstrate conformity with the EU MDR.
Understanding the distinction between these activities is essential. Clinical Investigation contributes evidence to the Clinical Evaluation process, but it does not replace it. The results of any Clinical Investigation must still be critically appraised alongside all other available evidence before conclusions are documented within the Clinical Evaluation Report (CER).
Clinical Evaluation and Clinical Investigation Compared
| Clinical Evaluation | Clinical Investigation |
|---|---|
| Continuous lifecycle process. | A specific clinical study conducted over a defined period. |
| Required for every medical device under the EU MDR. | Required only where existing clinical evidence is insufficient or additional evidence is necessary. |
| Reviews all available clinical evidence. | Generates new clinical evidence. |
| Includes literature, PMS, PMCF, vigilance and clinical investigations. | Involves recruiting participants and collecting prospective clinical data. |
| Results are documented within the Clinical Evaluation Report (CER). | Results are documented in a Clinical Investigation Report and feed into the Clinical Evaluation. |
| Continues throughout the device lifecycle. | Ends once the investigation is completed and reported. |
When Is a Clinical Investigation Required?
Whether a Clinical Investigation is required depends on the availability and quality of existing clinical evidence. Manufacturers should consider conducting a Clinical Investigation where:
- The device incorporates a novel technology or innovative mechanism of action.
- Existing scientific literature is insufficient to demonstrate safety or clinical performance.
- Equivalence to another device cannot be adequately justified.
- Additional evidence is needed to support new indications or expanded intended use.
- Evidence gaps have been identified during the Clinical Evaluation.
- The Notified Body or Competent Authority requires further clinical evidence.
For many established medical devices, particularly those based on well-understood technologies with substantial post-market experience, a robust Clinical Evaluation can often be supported using published literature, PMS and PMCF data without the need for a new Clinical Investigation.
Working Together to Demonstrate Compliance
Rather than viewing Clinical Evaluation and Clinical Investigation as separate regulatory activities, manufacturers should consider them as complementary parts of the same evidence-generation process. Clinical Investigation provides new clinical data where required, while Clinical Evaluation brings together all available evidence to determine whether the device continues to satisfy the General Safety and Performance Requirements (GSPRs) of the EU MDR.
By combining high-quality clinical investigations with published literature, post-market evidence and ongoing clinical follow-up, manufacturers can build a comprehensive body of evidence that supports CE marking and demonstrates continued compliance throughout the medical device lifecycle.
Keeping Up with the Latest MDR Clinical Evaluation Guidance?
The expectations for Clinical Evaluation continue to evolve through new Medical Device Coordination Group (MDCG) guidance. Discover the latest changes affecting Clinical Evaluation Reports (CERs), equivalence, clinical evidence, PMCF and Notified Body expectations in our Clinical Evaluation Under MDR: 2025 MDCG Updates.
Common Clinical Evaluation Mistakes and How to Avoid Them
Preparing a Clinical Evaluation under the EU MDR can be challenging, particularly for manufacturers transitioning from the Medical Devices Directive (MDD) or those developing innovative technologies. Notified Bodies frequently identify deficiencies in Clinical Evaluation Reports (CERs) that delay certification or result in requests for additional evidence.
Many of these issues are avoidable with careful planning, a robust Clinical Evaluation Plan (CEP) and a systematic approach to collecting, appraising and maintaining clinical evidence throughout the device lifecycle.
Common Clinical Evaluation Pitfalls
| Common Mistake | Best Practice |
|---|---|
| Relying on outdated clinical evidence | Regularly review scientific literature, PMS and PMCF data to ensure conclusions remain current. |
| Poorly defined intended purpose | Clearly define the device’s intended purpose, indications, users and target patient population before beginning the evaluation. |
| Insufficient literature search strategy | Develop a documented, reproducible search methodology with defined databases, keywords and inclusion/exclusion criteria. |
| Failure to critically appraise evidence | Assess the quality, relevance and scientific validity of every evidence source rather than simply summarising publications. |
| Weak justification of equivalence | Only claim equivalence where all technical, biological and clinical characteristics can be fully demonstrated in accordance with the MDR. |
| Ignoring post-market evidence | Integrate complaints, vigilance, PMS and PMCF findings into the Clinical Evaluation Report. |
| Treating the CER as a one-off document | Review and update the Clinical Evaluation whenever significant new evidence becomes available. |
| Poor alignment with Risk Management | Ensure identified clinical risks, residual risks and benefit-risk conclusions remain consistent with the ISO 14971 Risk Management File. |
What Notified Bodies Commonly Look For
During conformity assessment, Notified Bodies do far more than check whether a Clinical Evaluation Report exists. They assess whether the evaluation has been conducted using a scientifically rigorous methodology and whether the conclusions are fully supported by objective clinical evidence.
Typical areas of scrutiny include:
- A clearly documented Clinical Evaluation Plan (CEP).
- Comprehensive and reproducible literature search strategies.
- Robust critical appraisal of all clinical evidence.
- Appropriate justification where equivalence is claimed.
- Clear demonstration of conformity with the General Safety and Performance Requirements (GSPRs).
- Integration of Risk Management, PMS and PMCF activities.
- Justification where a Clinical Investigation has not been performed.
- Evidence that the Clinical Evaluation Report is actively maintained throughout the product lifecycle.
Addressing these expectations from the outset significantly reduces the likelihood of major findings during Notified Body review and helps streamline the conformity assessment process.
Building a Strong Clinical Evaluation
A successful Clinical Evaluation is built on planning, transparency and continual improvement. Manufacturers should establish a clear evaluation methodology, gather evidence from multiple reliable sources and critically assess whether that evidence adequately demonstrates safety, clinical performance and an acceptable benefit-risk profile.
Rather than viewing Clinical Evaluation as a regulatory hurdle, organisations that integrate it into their Quality Management System and product lifecycle management are better positioned to maintain compliance, respond to emerging clinical evidence and support long-term market access under the EU MDR.
Preparing for Notified Body Review?
Clinical Evaluation is one of the most closely scrutinised elements of your Technical Documentation during conformity assessment. Learn how Notified Bodies assess Clinical Evaluation Reports (CERs), clinical evidence, Risk Management, Post-Market Clinical Follow-up (PMCF) and overall MDR compliance in our Guide to EU MDR Notified Bodies.
Conclusion
Clinical Evaluation is one of the most important regulatory activities undertaken by medical device manufacturers. Under the EU MDR, it is no longer sufficient to demonstrate safety and performance only at the point of CE marking. Manufacturers must establish a robust, evidence-based process that continually assesses whether their devices continue to achieve their intended purpose while maintaining an acceptable benefit-risk profile throughout their lifecycle.
A successful Clinical Evaluation combines high-quality scientific literature, clinical investigations where appropriate, Post-Market Surveillance (PMS), Post-Market Clinical Follow-up (PMCF), vigilance data and Risk Management into a single, structured assessment. This evidence is documented within the Clinical Evaluation Report (CER), which forms a critical part of the Technical Documentation reviewed by Notified Bodies during conformity assessment.
Developing and maintaining a comprehensive Clinical Evaluation not only supports regulatory compliance but also provides valuable insight into real-world device performance, helping manufacturers identify opportunities for continual improvement, strengthen patient safety and maintain confidence in their products.
Whether you are preparing your first Clinical Evaluation Report, updating existing documentation for EU MDR compliance or responding to Notified Body observations, adopting a structured lifecycle approach will help ensure your clinical evidence remains robust, current and defensible.
At Patient Guard, our regulatory specialists support manufacturers throughout every stage of the Clinical Evaluation process—from developing Clinical Evaluation Plans (CEPs) and conducting systematic literature reviews to preparing Clinical Evaluation Reports (CERs), supporting Clinical Investigations and integrating Post-Market Clinical Follow-up (PMCF) into your Quality Management System. We help manufacturers build clinical evidence that not only satisfies regulatory requirements but also supports long-term market success under the EU MDR.
How Can Patient Guard Help?
Patient Guard supports medical device manufacturers throughout every stage of the clinical evaluation process.
Our experienced regulatory consultants can assist with:
- Clinical Evaluation Plans (CEP)
- Clinical Evaluation Reports (CER)
- Literature searches and critical appraisal
- State of the Art assessments
- Clinical evidence gap analysis
- PMCF planning and reporting
- Clinical strategy development
- EU MDR and UK regulatory compliance
- Technical Documentation preparation
- Notified Body readiness
Whether you are developing a new medical device or maintaining an existing product, our team can help you generate robust clinical evidence that supports successful regulatory approval and ongoing compliance.
Frequently Asked Questions About Medical Device Clinical Evaluation
Clinical Evaluation is the systematic and ongoing process of collecting, appraising and analysing clinical data to demonstrate that a medical device is safe, performs as intended and provides an acceptable benefit-risk profile throughout its lifecycle. It is a mandatory requirement under Article 61 and Annex XIV of Regulation (EU) 2017/745 (EU MDR).
Yes. Every medical device placed on the EU market under the MDR requires a Clinical Evaluation. However, the depth and complexity of the evaluation should be proportionate to the device’s classification, intended purpose, level of innovation and associated clinical risks.
The Clinical Evaluation Plan (CEP) defines how the Clinical Evaluation will be performed, including the objectives, methodology and evidence sources. The Clinical Evaluation Report (CER) documents the completed evaluation, summarises the clinical evidence reviewed and presents the manufacturer’s conclusions regarding safety, clinical performance and benefit-risk.
No. A Clinical Investigation is only required when existing clinical evidence is insufficient to demonstrate conformity with the EU MDR. Many established devices can rely on published literature, Post-Market Surveillance (PMS), Post-Market Clinical Follow-up (PMCF) and other clinical evidence, provided it adequately supports the device’s intended purpose and clinical claims.
The Clinical Evaluation Report should be reviewed and updated whenever significant new clinical information becomes available, such as new scientific literature, PMCF findings, Post-Market Surveillance data, vigilance reports or changes to the device or its intended purpose. Regular updates form part of the manufacturer’s lifecycle obligations under the EU MDR.
Clinical evidence may include scientific literature, Clinical Investigations, equivalent device data (where appropriately justified), Post-Market Surveillance, Post-Market Clinical Follow-up, device registries, real-world clinical experience and vigilance data. Manufacturers should evaluate all relevant evidence collectively rather than relying on a single source.
PMCF is used to collect additional clinical data after a device has been placed on the market. It helps confirm the continued safety, clinical performance and benefit-risk profile of the device while identifying emerging risks or opportunities for improvement throughout its lifecycle.
Clinical Evaluation and Risk Management are closely linked. Clinical evidence is used to verify that identified risks remain acceptable when balanced against the clinical benefits of the device. Likewise, Risk Management identifies hazards that should be considered during the Clinical Evaluation process.
Notified Bodies assess whether the Clinical Evaluation has been conducted using a robust scientific methodology. They typically review the Clinical Evaluation Plan, literature search strategy, evidence appraisal, benefit-risk analysis, Clinical Evaluation Report, PMS, PMCF activities and the overall integration of Clinical Evaluation within the Technical Documentation.
Yes, provided the available literature is relevant, scientifically robust and sufficient to demonstrate the safety and clinical performance of the device. Manufacturers must critically appraise the quality of the evidence and justify why it adequately supports conformity with the EU MDR.
Clinical Evaluation is primarily governed by Article 61 and Annex XIV of Regulation (EU) 2017/745. Manufacturers should also consider relevant MDCG guidance documents, MEDDEV 2.7/1 Rev. 4 (where applicable) and harmonised standards that support the clinical evaluation process.
Yes. Patient Guard provides comprehensive Clinical Evaluation support for manufacturers of medical devices and in vitro diagnostic medical devices. Our services include Clinical Evaluation Plans (CEPs), Clinical Evaluation Reports (CERs), systematic literature reviews, clinical evidence gap assessments, PMCF planning, Clinical Investigation support and ongoing lifecycle updates to help maintain compliance with the EU MDR and UK Medical Devices Regulations.
References
This guide is based on the following legislation, international standards and official regulatory guidance relating to clinical evaluation, clinical evidence and Post-Market Clinical Follow-up under Regulation (EU) 2017/745 (MDR).
| Organisation | Reference | Why it's relevant |
|---|---|---|
| European Union | Regulation (EU) 2017/745 on Medical Devices (MDR) | Provides the legal framework for clinical evaluation under Article 61 and Annex XIV, including Clinical Evaluation Plans, Clinical Evaluation Reports, clinical evidence, equivalence, clinical investigations and Post-Market Clinical Follow-up. |
| European Commission | MEDDEV 2.7/1 Rev. 4 – Clinical Evaluation: A Guide for Manufacturers and Notified Bodies | Provides the established methodology for planning, conducting, documenting and updating clinical evaluations, including literature searching, appraisal of clinical data, analysis of evidence and preparation of Clinical Evaluation Reports. Although published under the former Directives, relevant sections continue to be referenced under the MDR where consistent with current legislation. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-6 – Guidance on Sufficient Clinical Evidence for Legacy Devices | Explains how manufacturers should determine and justify a sufficient level of clinical evidence, including the use of pre-market and post-market clinical data to demonstrate conformity with the MDR. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-5 – Guidance on Clinical Evaluation and Equivalence | Provides detailed guidance on demonstrating technical, biological and clinical equivalence and documenting the comparison with an equivalent device within the Clinical Evaluation Report. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-7 – Post-Market Clinical Follow-up Plan Template | Provides an official template and guidance for planning Post-Market Clinical Follow-up activities to confirm the continued safety, clinical performance and benefit-risk acceptability of medical devices after they have been placed on the market. |
| Medical Device Coordination Group (MDCG) | MDCG 2020-8 – Post-Market Clinical Follow-up Evaluation Report Template | Provides an official structure for documenting PMCF findings and explains how those findings should feed back into the Clinical Evaluation Report, risk management documentation and post-market surveillance activities. |
| International Organization for Standardization (ISO) | ISO 14155:2026 – Clinical Investigation of Medical Devices for Human Subjects – Good Clinical Practice | Defines internationally recognised Good Clinical Practice requirements for designing, conducting, recording and reporting clinical investigations used to generate clinical evidence for medical devices. |
Clinical evaluation requirements continue to evolve through legislation, recognised standards and regulatory guidance. Manufacturers should always consult the latest published legislation, international standards and official guidance when planning clinical evaluations, assessing clinical evidence, conducting clinical investigations and maintaining Clinical Evaluation Reports throughout the medical device lifecycle.
Patient Guards Recent Posts
IVDR Performance Evaluation Explained: A Complete Guide for Manufacturers
Performance Evaluation is one of the most important requirements under the EU In Vitro Diagnostic Regulation (IVDR). Every manufacturer must demonstrate that their in vitro diagnostic medical device achieves its intended purpose through robust scientific validity, analytical performance and clinical performance evidence. This guide explains every stage of IVDR Performance Evaluation, including Performance Evaluation Plans (PEPs), Performance Evaluation Reports (PERs), Post-Market Performance Follow-up (PMPF) and how Performance Evaluation supports successful CE marking under Regulation (EU) 2017/746.
IVDR Classification Explained: A Complete Guide to Class A, B, C and D IVDs
Understanding how your in vitro diagnostic device is classified under the EU IVDR is one of the first and most important steps towards regulatory compliance. This guide explains the IVDR classification rules, the differences between Class A, B, C and D IVDs, how Annex VIII is applied, and how classification affects conformity assessment, technical documentation and Notified Body involvement.
When Do You Need New Biocompatibility Testing for a Medical Device?
A material change, supplier switch, manufacturing transfer or design modification does not automatically require new ISO 10993 biocompatibility testing. Learn how manufacturers use Biological Evaluation Plans (BEPs), chemical characterisation, toxicological risk assessments and Biological Evaluation Reports (BERs) to determine whether existing biological evidence remains valid or whether additional testing is required under ISO 10993-1, the EU MDR and FDA expectations.
Patient Guards Related Services
Patient Guards Regulatory Tools
Need Training?
Do you need training on Quality Management Systems or EU MDR/ EU IVDR? then check out our training courses.
